We would love to hear your thoughts about our site and services, please take our survey here.
That is my understanding miavoce and the reason for my question a couple of days ago.
Parsortix harvests the cells and then a downstream assay determines the HER2 status - sequential processes. The laboratory accreditation should supply the validation necessary to apply results to determine the treatment regime.
However, as another posted MBC is probably the most prolific form of cancer so, sadly, no shortage of patients.
Parsortix may also have a role to play with solid biopsy samples - I remember an RNS a number of years ago where a research department was having success with a process whereby solid samples were, I think the term was dissociated,(think blender or smoothie maker!) and the resultant slurry was then run through a Parsortix cassette, apparently with great success. This had the potential to short circuit the normal process of preparing and examining a number of microscope slides to detect CTCs using fallible human eyes.
Let's hope that Parsortix can play a vital role in what could be a game changer with AZNs new treatment.
All IMHO
Would I be right in thinking that since Enhertu is tumour agnostic and the only information required for successful treatment is the tumour HER2 status, that Parsortix could be applied to CTC detection in all cancer types?
An enlightening post Bermuda. Thanks.
Just a couple of things I may not have made clear.
I wasn't having a go at the BOD - it was the comment "anyone can buy a piece of the pie" that I pointed out that PIs also had to work tirelessly to earn the dosh to invest in the pie.
By lack of activity, I was referring to the SP activity and it's disconnect from progress and positive news.
I should have made myself clearer.
All IMHO
Dibs.
'Why bother with a long term partnership'?
Would you think any partnership would be exclusive?
It seems to me that Parsortix would potentially disrupt some of Abbot's (or any other partner) existing business and the rate of any developments would be tempered with a view to minimising damage elsewhere in their organisation. At the same time, there would be no incentive to grow the SP and a temptation to wear down IIs prior to making an offer to buy out.
Multiple partnerships would introduce an element of competition and move things forward much more rapidly and give the participating companies a much clearer idea of the value of Angle.
BOJO Excellent post, but I would disagree with your statement that while anyone can buy a piece of the pie, the BOD work tirelessly.
Working tirelessly is how most IIs make the money to invest here (unless you've won the lottery or turned over a Post Office) .
The seeming, current lack of activity can be exasperating for investors, but keep in mind that people are dying who could potentially have had their lives saved or extended if this technique was more generally adopted.
All IMHO
Faicj.
I've been in here for over twelve years and although I've had a few topups at these rock bottom prices, I'm still well under water.
My late wife would have benefitted (as would most cancer sufferers) from PBT and that was my principle reason for investing - just such a shame it has taken so long to get here.
If I can get some of my money back and a working machine then I'll be more than happy.
If you're looking for a dabble and a punt, Galileo Resources will provide guaranteed excitement!
DYOR and all IMHO
A very unpolished presentation Meldrew.
When someone says 'ehm' every second or third word, you can't help forming the impression that they're making it up as they go along or just not altogether sure what they're talking about.
After all of the slipped deadlines and ambiguous time scales I would have expected to hear a brisk, confident statement to reassure nervous investors.
All IMHO
Cancer will directly affect over one in four people and indirectly affect almost everyone over their lifetime.
Has it not occurred to the gloateurs and fantasists that come out of the woodwork when the sp drops that many people invested here are more interested in the technology and potential impact on treatment than turning a quick buck. These investors are unlikely to be panicked by the transparent efforts of the merchants of doom who seize on any sp glitch to spread tales of woe.
Everyone likes to make money, and no doubt there are many trading this share, but LTHs on here are likely to be seeing the bigger picture, sitting back and smiling.
All IMHO
I seem to remember an RNS a couple of years back outlining a procedure to simplify the examination of a solid biopsy. The normal procedure would be FFPE sample preparation which would then be sliced up and mounted on a series of microscope slides which would be examined to detect tumour cells.
The paper described a process - dissolution I think they termed it but probably a blitz in a kitchen blender!
The resultant sample slurry was then run through a Parsortix instrument and any tumour cells in the sample were captured in the cassette. Only one slide to examine. It seemed that the process was quite reliable.
It does make you wonder what's going on here Drums.
Another RNS demonstrating a valuable application in the monitoring of SCLC and yet the price still slides.
That said, I'm putting every bean I can lay my hands on into here at these fire sale prices.
Good luck to those with sufficient nerve not to be rattled by current happenings.
All IMHO
Oilbagger
If there was an early placing like you suggest, could you, or any other contributor, predict what the terms would be?
Is there a standardised formula for these events?
I hope this isn't a dumb question, I just want to be sure I have an adequate wedge in place to enable me to take up my allocation. Exciting times. GLA.
Left feeling like he'd been booted up the a#se and pi##ing blood for a week is how my friend described his prostate biopsy.
If this procedure (which must cost well over £1000 to perform) can be replaced by a Parsortix test then patients, hospital boards and shareholders are all going to be winners. All IMHO
OHG
It's not just the final findings that will be of importance, it's what discoveries might be made along the way.
CTC capture might replace solid biopsy ( the thought of which procedure makes my eyes water) and early findings might translate into improved treatment and monitoring.
3-5 years is a fairly short timescale IMO.
Novel drugs for cancer treatment is a huge focus in the industry, but all roads lead back to Angle for monitoring and assessment IMHO.